Last reviewed · How we verify

Ropivacaine/Fentanyl

National Institute for Tuberculosis and Lung Diseases, Poland · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve membranes, while fentanyl is an opioid agonist that binds to mu opioid receptors to provide analgesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve membranes, while fentanyl is an opioid agonist that binds to mu opioid receptors to provide analgesia. Used for Regional anesthesia and analgesia for surgical procedures, Postoperative pain management.

At a glance

Generic nameRopivacaine/Fentanyl
Also known asROPIVACAINE HYDROCHLORIDE 10 mg/ml
SponsorNational Institute for Tuberculosis and Lung Diseases, Poland
Drug classLocal anesthetic with opioid analgesic combination
TargetVoltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly inhibits sodium influx into nerve fibers, preventing depolarization and blocking pain signal transmission. Fentanyl enhances this effect by activating mu opioid receptors in the central and peripheral nervous system, providing additional analgesia and potentially reducing the required local anesthetic dose. This combination is used for regional anesthesia and analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: